Drugs / NNC0114-0006
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01689025 | Sep 2012 → Feb 2014 | systemic lupus erythematosus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1 | NCT01565408 | Mar 2012 → Oct 2013 | rheumatoid arthritis | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02443155 | Nov 2015 → Aug 2018 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT01751152 | Feb 2013 → Dec 2014 | Crohn disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT01647451 | Sep 2012 → Aug 2013 | rheumatoid arthritis | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0114-0006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01565408 ↗ |
| Known as | NN-8828 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297797 ↗ |
| Known as | NN-9828 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297797 ↗ |
| Route | Subcutaneous | “Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.” NCT01565408 ↗ |
| Target | IL21 | “anti-interleukin (IL)-21 antibody” PMID 33662334 ↗ Mar 2021 |